CD71-Binding FN3 Domains for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches lack specific and efficient methods to target CD71 for drug delivery and tissue-specific treatment, particularly for cancer and neurological conditions.
Innovation Solution
Development of FN3 domains that specifically bind to CD71, allowing for receptor-mediated internalization and potential therapeutic delivery to CD71-expressing cells, including cancer cells and cells of the central nervous system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies or antibody fragments are used to target CD71, then high affinity and specificity for CD71 binding are achieved, but the therapeutic approach lacks tissue-specific delivery capability and has limited intracellular access
Solution Approach 1:
The antibody is segmented into smaller functional units: a CD71-binding domain (derived from the antibody variable region) and an FN3 domain. This segmentation allows the binding function to be separated from the delivery function, enabling the FN3 domain to mediate tissue-specific delivery while the CD71-binding domain maintains high affinity binding. The segmented approach resolves the contradiction by allowing each domain to specialize in one function.
Solution Approach 2:
The FN3 domain acts as an intermediary between the CD71-binding domain and the target tissue. It mediates tissue-specific delivery by interacting with both the CD71 receptor and tissue-specific factors, bridging the gap between high-affinity binding and tissue-specific delivery capabilities. This intermediary function allows the system to achieve both binding reliability and delivery versatility.
2Productivity
If high affinity antibodies are used for CD71 targeting, then receptor internalization is enhanced, but normal receptor trafficking is altered causing degradation instead of recycling
Solution Approach 1:
The invention uses partial action by employing only the essential binding domain of the antibody rather than the full antibody structure. This partial engagement with the CD71 receptor achieves sufficient internalization efficiency without the excessive action that would disrupt normal trafficking. The reduced size and modified structure of the CD71-binding domain allow it to trigger internalization while avoiding the lysosomal degradation pathway activated by full antibodies.
3Ease of manufacture
If non-antibody proteins are engineered to bind CD71, then advantages in size, stability, and ease of conjugation are achieved, but specific high-affinity binding to CD71 is not initially present
Solution Approach 1:
The invention copies the CD71-binding capability from the antibody variable region into a different protein scaffold (the FN3 domain). By copying the essential binding motifs and structural features responsible for CD71 recognition, the FN3 domain achieves high-affinity binding while maintaining the manufacturing advantages of non-antibody proteins. This copying approach transfers the binding function to a more manufacturable platform.
Solution Approach 2:
The invention changes the fundamental parameters of the binding protein by transitioning from an antibody-based system to an FN3 domain-based system. This parameter change includes altering the protein scaffold, size, structural composition, and expression system compatibility. These parameter changes enable easier manufacturing, conjugation, and stability while the binding affinity is maintained through careful design of the CD71-interacting residues in the FN3 domain.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FN3 domains achieve specific binding to CD71 with high affinity, enabling targeted delivery of therapeutic agents to CD71-expressing cells, thereby improving treatment specificity and efficacy for various diseases.
Implementation Method 1
FN3 domains (e.g., polypeptides) that specifically bind CD71 protein
Data Source
AI summary
The present disclosure relates to polypeptides, such as fibronectin type III (FN3) domains that can bind CD71, their conjugates, isolated nucleotides encoding the molecules, vectors, host-cells, as well as methods of making and using the same.